FIELD: medicine, hepatology.
SUBSTANCE: invention relates to treatment of chronic hepatitis C. Method involves administration in a patient α2A-interferon modified with polyethylene glycol (PEG)(conjugate PEG-IFN-α2A) in combination with ribavirin. Method provides the prolonged clearance of virus that promotes both activity with respect to cells proliferation and effective treatment of disease.
EFFECT: enhanced effectiveness of preparation.
2 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING TYPE III PEGYLATED INTERFERONS FOR TREATING HEPATITIS C | 2009 |
|
RU2496514C2 |
| APPLICATION OF CYCLOSPORINE AND PEGYLATED INTERFERON COMBINATION FOR HEPATITIS (HCV) TREATMENT | 2005 |
|
RU2394589C2 |
| PREVENTIVE OR THERAPEUTIC AGENT AGAINST VIRAL DISEASE | 2007 |
|
RU2433827C2 |
| METHOD OF TREATING CHRONIC VIRAL HEPATITIS C WITH MEDICATIONS IN LIPOSOMAL FORM | 2011 |
|
RU2475263C1 |
| METHOD OF PREDICTING INTERFERON-RIVABIRIN-INDUCED NEUROPENIA IN PATIENTS WITH CHRONIC HEPATITIS C OBTAINING COMBINED ANTIVIRAL THERAPY | 2011 |
|
RU2444998C1 |
| DOSAGE FORMS | 2005 |
|
RU2393863C2 |
| SYNTHETIC VERSIONS OF HYPERGLYCOLISED PROTEASE-RESISTIVE POLYPEPTIDE, ORAL COMPOSITIONS AND METHODS OF USING SUCH VERSIONS | 2005 |
|
RU2392963C2 |
| NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON | 2010 |
|
RU2447083C1 |
| SINGLE NUCLEOTIDE POLYMORPHISM ON CHROMOSOME 15 ENABLING PREDICTION OF HCV TREATMENT RESPONSES | 2012 |
|
RU2606759C2 |
| METHOD OF PREDICTING DEVELOPMENT OF NEUTROPENIA, CAUSED BY COMBINED ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C | 2011 |
|
RU2449278C1 |
